The global challenge of HIV/AIDS remains one of the most pressing public health issues today. According to the latest data from UNAIDS, around 38.4 million people worldwide are living with HIV/AIDS, underlining the need for not only medical intervention but also comprehensive awareness, education, and social change. Despite the significant strides made in treatment and prevention, the confusion surrounding the relationship between HIV and AIDS still persists.

Young people have become influential advocates in the fight against HIV/AIDS. Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities. These young activists utilize digital platforms and peer-to-peer education to dispel myths, promote safe practices, and foster supportive environments for those affected by HIV/AIDS.

Dr Gowri Kulkarni, an expert in Internal Medicine, explains that while the terms HIV and AIDS are often used interchangeably, they are distinctly different. "HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, whereas AIDS (Acquired Immunodeficiency Syndrome) is a condition that occurs when HIV severely damages the immune system," she clarifies. To understand the implications of these differences, it's important to explore the fundamental distinctions between the two.

1. HIV is a Virus; AIDS is a Syndrome

HIV is the virus responsible for attacking the body’s immune system, specifically targeting CD4 cells, which are crucial for the body’s defense against infections. As HIV progresses, it destroys these cells, weakening the immune system over time. If left untreated, this continuous damage can lead to AIDS.

AIDS, on the other hand, is a syndrome, not a virus. Dr Kulkarni further elaborates that AIDS is a collection of symptoms and illnesses that emerge when the immune system is severely compromised due to prolonged HIV infection. It represents the most advanced stage of HIV, and is characterized by very low CD4 counts or the onset of opportunistic infections like tuberculosis, pneumonia, or certain cancers.

2. Not Everyone with HIV Develops AIDS

A key distinction to remember is that not everyone with HIV will progress to AIDS. Thanks to advancements in medicine, particularly antiretroviral therapy (ART), individuals living with HIV can manage the virus and maintain a healthy immune system for many years, or even decades, without ever developing AIDS. ART works by suppressing the virus to undetectable levels, effectively preventing the damage HIV would otherwise cause to the immune system.

Without treatment, however, HIV progresses through three stages:

- Acute HIV Infection: This stage occurs shortly after transmission and may include symptoms like fever, fatigue, and swollen lymph nodes.

- Chronic HIV Infection: Often asymptomatic or mildly symptomatic, the virus continues to damage the immune system but at a slower rate.

- AIDS: This is the final stage, marked by severe immune damage and the presence of infections that take advantage of the compromised immune defenses.

3. HIV is Transmissible; AIDS is Not

Another key distinction between HIV and AIDS is the way in which they are transmitted. HIV is highly contagious and can be transmitted through the exchange of bodily fluids such as blood, semen, vaginal fluids, and breast milk. It is primarily spread through unprotected sexual contact, sharing needles, or from mother to child during childbirth or breastfeeding.

AIDS, however, is not transmissible. It is not a disease that can be passed from one person to another. Rather, AIDS is the result of untreated, advanced HIV infection and is a direct consequence of the virus’s damage to the immune system.

4. Diagnosis Methods Differ

HIV and AIDS are diagnosed through different methods. HIV is diagnosed through blood tests or oral swabs that detect the presence of the virus or antibodies produced by the immune system in response to the virus. Early detection of HIV is crucial, as it allows for timely intervention and treatment, which can prevent the virus from progressing to AIDS.

AIDS, on the other hand, is diagnosed using more specific criteria. Dr Kulkarni notes that the diagnosis of AIDS is made when the individual’s CD4 cell count falls below 200 cells/mm³, or when opportunistic infections or certain cancers (such as Kaposi's sarcoma or lymphoma) are detected. Diagnosing AIDS involves a more thorough assessment of the individual’s immune function and overall health, as opposed to just the detection of HIV.

5. Treatment Goals Are Different

The treatment goals for HIV and AIDS differ significantly, although both involve antiretroviral therapy (ART). For HIV, the primary treatment goal is to suppress the virus to undetectable levels, thus maintaining a strong immune system and preventing further transmission of the virus. People living with HIV can often live long, healthy lives if they adhere to ART.

For individuals diagnosed with AIDS, the treatment plan becomes more complex. While ART remains an essential part of managing the virus, treatment for AIDS also focuses on addressing the opportunistic infections and secondary health complications associated with severe immune suppression. The goal of treatment for AIDS is not only to manage the HIV virus but also to improve the quality of life and extend survival by treating these secondary health issues.

Role of Community Engagement in Combatting HIV/AIDS

While the medical community has made great strides in managing HIV, the battle to curb its transmission is also a social and cultural issue. Dr Daman Ahuja, a public health expert, highlights that HIV/AIDS awareness and education are vital to reducing transmission rates and supporting those affected by the virus. "Young people, especially, have become key advocates in the fight against HIV/AIDS," says Dr Ahuja. "Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities."

Additionally, grassroots activism plays a significant role in raising awareness and addressing stigma. As the World Health Organization reports, community-based interventions have been proven to increase HIV testing rates and improve treatment adherence, which are crucial in the fight against the pandemic.

The ultimate goal of organizations like UNAIDS is to eliminate the HIV/AIDS pandemic by 2030. Achieving this requires global collaboration, from medical treatment advancements to public health strategies, education, and advocacy. Dr Kulkarni’s insight underscores the importance of early detection, treatment adherence, and community support in the fight against HIV/AIDS.

Dr Gowri Kulkarni is Head of Medical Operations at MediBuddy and Dr Daman Ahuja, a public health expert and has been associated with Red Ribbon Express Project of NACO between 2007-12.

Higher temperatures in the US could increase heat-related heart disease by 200 per cent by 2050, according to an alarming study.

The research, published in JAMA Cardiology, predicts rising temperatures driven by climate change will dramatically increase heat-related heart disease in the US.

It is already known that extreme heat is detrimental to heart health and can potentially trigger heart attacks and other cardiovascular events.

"But this study is the first to map out exactly how bad the problem could get—county by county, across the US. It also highlighted how states with lower median household incomes are likely to face higher heat-related heart disease burden," said Gokul Parameswaran, research associate at the Case Western Reserve School of Medicine's Cardiovascular Research Institute and the study's lead author.

Regional Hot Spots

Researchers analyzed heart disease data in each county in the contiguous US from 2010 to 2016 to develop projections through 2050.

They found that the Pacific Northwest has the highest heat-related heart disease rate in the country. Southern states, however, are projected to see the steepest increases by 2050.

"Climate change is not just an environmental issue—it is a health equity crisis, and prioritizing vulnerable communities must be at the center of any heat mitigation strategy," said Salil Deo, associate professor in the Department of Surgery.

Also read: Global Temperatures Likely To Stay Near Record Levels For Next Five Years: WMO

The study also found that aging — independent of temperature increases — will contribute an additional 34 per cent increase in heat-related heart disease by 2050, simply because there will be more older adults by then.

Heat Events In The US

The study comes amidst more frequent heat events in the US, which is also lasting longer, and the temperatures during heat events are going up.

The past 10 years, from 2015 to 2024, were the hottest on record globally. But in cities across the United States, the average rate of extreme heat events increased from two per year in the 1960s to 10 per year between 2010 and 2020, according to Center for Climate and Energy Solutions (C2ES), a Washington-based NGO.

Also Read:‘Heat Dome’ Triggering Record-Breaking May Temperatures In France, UK, Spain

Additionally, as of 2024, the average length of heat-wave season in the US has increased by 46 days since the 1960s.

How Does Heat Raise Heart Risks?

According to the Centers for Disease Control and Prevention, when temperatures rise, the heart must work harder to keep the body cool, and the likelihood of developing sudden clots in the bloodstream increases.

Read More: Can Extreme Heat Trigger Heart Palpitations? Expert Explains Risks

This extra stress on the heart due to high heat may lead to heart attacks or sudden worsening of heart disease, especially in the elderly or those with prior heart conditions.

How To Tackle The Risk

• Expanding green spaces and tree cover in urban areas could help reduce temperature-related adverse effects.
• Expanding access to cooling centers and air-conditioning assistance programs for low-income communities can also help bridge the gap in underserved communities.

"Climate change is not a distant, abstract threat," said Sanjay Rajagopalan, director of the Cardiovascular Research Institute and chief of Cardiovascular Medicine at University Hospitals Harrington Heart & Vascular Institute.

"It is a present and growing danger to the hearts of every American, and it is coming for the most vulnerable among us first. The choices made today about greenhouse gas emissions, urban planning, and health care policy will determine whether tens of thousands of Americans live or die from heat-related heart disease by 2050," he added.

Diabetes is not only a disorder affecting blood sugar levels, but it also increases the risk of heart disease. People who have diabetes are more prone to get affected by heart attack, stroke, high blood pressure, and blockage of arteries than people without diabetes. Because of this strong link, diabetes care needs a focus on both blood sugar control and heart care.

One of the biggest improvements in diabetes care is the use of GLP-1 receptor agonist therapies. These medications not only help to control sugars but also reduce the risk of heart disease. When a person combines GLP-1 treatment along with a healthy lifestyle, they can improve their overall well-being and lead a good quality of life.

Understanding the Link Between Type 2 Diabetes and Heart Disease

Type 2 diabetes and heart disease are interlinked. Diabetes increases heart disease risk by 2 to 4 times. Over a period of time, when the sugars are chronically high, blood vessels and nerves that support the heart get damaged. Many individuals with diabetes also have additional risk factors, such as:

• Obesity
• High blood pressure
• High cholesterol
• Physical inactivity

These conditions can make a person vulnerable to a heart attack and stroke. Studies show that people with Type 2 diabetes are nearly twice as likely to develop heart disease compared to those without diabetes.

What Are GLP-1 Therapies?

GLP-1 receptor agonists are medications to control high blood sugar in people with type 2 diabetes. These therapies help by:

• Increasing insulin release when blood sugar rises
• Delaying stomach emptying
• Reducing appetite
• Decreasing glucagon production
• Improving weight loss

GLP-1 therapies help control blood sugar. Beyond this, these treatment regimens provide many more benefits. Research shows that these medications can reduce the risk of major cardiovascular events such as heart attack and stroke.

In addition, GLP-1 therapies help in weight reduction. Obesity is also linked to diabetes and heart disease. Hence, GLP-1 therapies help to reduce weight and the risk of developing heart diseases.

Importance of Lifestyle Changes

Medications are important in controlling blood sugars. However, the medication therapies need to be combined with a healthy lifestyle, which can remain the foundation of diabetes and heart disease care.

Healthy Nutrition

A balanced, healthy plate can improve blood sugar, cholesterol, and blood pressure levels. Individuals with diabetes are encouraged to include:

Whole grains

Vegetables and fruits

Lean proteins

Nuts and seeds

Healthy fats

By restricting sugars, processed and ultra-processed foods, extra salt, and unhealthy trans-fats, one can reduce weight and support heart health.

Regular Physical Activity

Regularized physical activity routines help improve insulin sensitivity and strengthen the heart. Activities like walking, cycling, swimming, yoga, and strength training can help reduce the risk of heart disease. Experts generally recommend at least 150 minutes of moderate exercise every week.

Weight Management

Even small amounts of weight loss can improve blood sugar control and reduce stress on the heart. The combination of GLP-1 therapies, healthy lifestyle, controlled eating, and regular exercise gives better long-term results.

Conclusion

Type 2 diabetes and heart disease are closely interlinked, making complete diabetes care essential. GLP-1 therapies are changing diabetes management by offering benefits beyond glycemic control, including heart protection and weight reduction.

However, tablets and medicines alone cannot do all the work. Healthy lifestyle changes, such as balanced nutrition, regular physical activity, and proper weight management, must contribute equally. GLP-1 therapies and lifestyle changes can significantly reduce heart-related risks and improve overall well-being in individuals with Type 2 diabetes.

Multiple Sclerosis (MS) is a chronic neurological condition in which the immune system attacks the central nervous system, leading to symptoms such as fatigue, chronic pain, bladder disturbances, gait imbalance, and blurry vision, among others. These symptoms fluctuate, progress over time, become life-limiting, and are not always outwardly visible.

Growing evidence shows that early diagnosis and timely initiation of high-efficacy therapies (HETs) can slow disease progression, reduce relapses, and preserve long-term neurological function. For many individuals living with MS, the struggle goes beyond simply managing their condition. It is also about whether the full impact of the disease is adequately recognized and understood by policymakers, healthcare systems, and the public at large.

Although MS is recognized as a disability under the Rights of Persons with Disabilities (RPwD) Act, 2016, people living with MS (PwMS) continue to face difficulties accessing disability-related support because their symptoms are not always consistent, visible, or measurable during assessment. This is particularly relevant in a condition like MS, where some of the most disabling symptoms remain invisible.

Living with an Unseen Disability

The effects of MS extend far beyond mobility issues alone. Fatigue, brain fog, memory problems, neuropathic pain, bladder dysfunction, visual disturbances, and emotional strain can significantly hinder a person's ability to work, engage socially, manage responsibilities, and fully participate in everyday activities.

One of the less understood aspects of MS is cognitive impairment, which affects a significant proportion of PwMS. MS causes inflammation in the brain and contributes to brain volume loss, thereby slowing processing speed, affecting concentration, impairing memory, and making planning or multitasking increasingly difficult. Even routine activities such as maintaining conversations, remembering instructions, or completing everyday tasks may become mentally exhausting.

Because many of these symptoms are episodic, variable, or invisible, PwMS may sometimes delay seeking specialist care, while the impact of the disease may also be underestimated by those around them. Yet, MS disease activity can continue even when symptoms appear intermittent or mild.

In MS, treatment decisions regarding the early initiation of the appropriate therapy (platform disease-modifying therapy versus high-efficacy therapy) can meaningfully influence long-term outcomes and quality of life.

Because slowing disease progression often requires highly potent intervention, evaluating a drug’s long-term safety profile becomes just as critical as its efficacy. Certain therapies may carry a risk of progressive multifocal leukoencephalopathy (PML)—a rare and potentially fatal viral brain infection that occurs under severe immunosuppression. Therefore, choosing a high-efficacy treatment with a favorable long-term safety profile is paramount.

When Clinical Reality and Functional Recognition Diverge

MS is inherently unpredictable. A person may appear physically stable during one evaluation but experience significant neurological difficulties during a relapse or disease flare-up.

In clinical practice, neurologists evaluate MS through disease progression, relapse patterns, imaging findings, and the EDSS scale (a standardized method used to quantify and measure the level of disability in PwMS).

Looking Ahead

Improving understanding of invisible symptoms in MS is important not only for social awareness but also for enabling patients to access timely care. Greater clarity, consistency, and sensitivity in approaches to chronic neurological conditions can help ensure that PwMS are better supported across healthcare, workplace, and social settings.

Earlier diagnosis, timely intervention, and stronger recognition of the day-to-day realities of living with MS can together help patients preserve dignity, maintain independence, and achieve better long-term outcomes.